Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$461.12 USD

461.12
2,573,707

+6.11 (1.34%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $459.58 -1.54 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Activision, Marriott, Intuitive Surgical, Edison International and TELUS

The Zacks Analyst Blog Highlights: Activision, Marriott, Intuitive Surgical, Edison International and TELUS

    Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025

    Weight Watchers' (WTW) plan to issue senior notes will aid the company in reducing cost of capital.

      Mark Vickery headshot

      Top Stock Reports for Activision, Marriott & Intuitive Surgical

      Today's Research Daily features new research reports on 16 major stocks, including Activision (ATVI), Marriott (MAR) and Intuitive Surgical (ISRG).

        Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

        Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.

          Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise

          Bruker's (BRKR) recent acquisition of Germany-based MERLIN buoys optimism for its growth within MALDI Biotyper business.

            AmerisourceBergen (ABC) Rewards Investors With Dividend Hike

            AmerisourceBergen's (ABC) dividend hike adheres to the company's policy of rewarding stakeholders at regular intervals.

              OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3

              OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

                Inogen Claims Top Position in Deloitte List on Solid Growth

                Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.

                  QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

                  QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.

                    TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y

                    TransEnterix's (TRXC) reports unimpressive Q3 results, thanks to the constriction of deferred service revenues.

                      Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife

                      Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.

                        Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down

                        Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.

                          Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag

                          Genomic Health (GHDX) gains from strong adoption of its Oncotype DX test in Q3.

                            Hill-Rom (HRC) Banks on Product Launches, Competition Rife

                            Hill-Rom (HRC) focuses on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging.

                              Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates

                              At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.

                                Globus Medical (GMED) Q3 Earnings In Line, View Reiterated

                                Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.

                                  Baxter Posts Solid Q3, Broad Product Spectrum Raises Hopes

                                  Baxter's (BAX) convenient kidney dialysis solutions, regenerative tissue products, 3-in-1 oXIRIS set for continuous renal replacement therapy are the latest additions to the extensive product portfolio.

                                    SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates

                                    SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.

                                      Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up

                                      Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.

                                        VWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure

                                        VWR's third-quarter report impresses with growth in Americas and EMEA-APAC segments. The transaction with Avantor is also in process.

                                          Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3

                                          Penumbra (PEN) witnesses strong growth across all geographical regions and product lines in Q3.

                                            DaVita (DVA) Q3 Earnings Miss & Revenues Beat, '17 View Dull

                                            Strong growth in patient services is likely to boost DaVita's (DVA) growth trajectory in the coming quarters. DaVita's (DVA) continuous improvement in Kidney care is commendable as well.

                                              Align Technology at 52-Week High: What's Driving the Stock?

                                              Align Technology (ALGN) consistently invests in R&D for product innovation.

                                                Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues

                                                Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.

                                                  Inogen (INGN) Beats Earnings and Revenue Estimates in Q3

                                                  Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.